antibody

Goat anti-MDM2 (isoform) Antibody

MBS420678

0.1 mg

300 USD

polyclonal

goat

nonconjugated

human, rat, dog, cow

western blot, enzyme immunoassay

Antibody

Goat anti-MDM2 (isoform) Antibody

MDM2

MDM2; Mdm2; transformed 3T3 cell double minute 2; p53 binding protein (mouse); HGNC: 6973; MGC71221; hdm2; mouse double minute 2 homolog; mouse double minute 2, human homolog of; p53-binding protein; p53-binding protein MDM2; ubiquitin-protein ligase E3 Md; MDM2 antibody; Mdm2 antibody; transformed 3T3 cell double minute 2 antibody; p53 binding protein (mouse) antibody; HGNC: 6973 antibody; MGC71221 antibody; hdm2 antibody; mouse double minute 2 homolog antibody; mouse double minute 2; human homolog of antibody; p53-binding protein antibody; p53-binding protein MDM2 antibody; ubiquitin-protein ligase E3 Mdm2 antibody; Mdm2 p53 binding protein homolog (mouse) antibody; HDMX antibody; MGC5370 antibody; Mdm2; transformed 3T3 cell double minute 2; p53 binding protein antibody; OTTHUMP00000183495 antibody; double minute 2; human homolog of antibody; MDM2 (isoform)

E3 ubiquitin-protein ligase Mdm2 isoform a; E3 ubiquitin-protein ligase Mdm2; E3 ubiquitin-protein ligase Mdm2; MDM2 proto-oncogene; Double minute 2 protein; Hdm2; Oncoprotein Mdm2; p53-binding protein Mdm2

MDM2

MDM2; MDM2; HDMX; hdm2; ACTFS; Hdm2

MDM2_HUMAN

Polyclonal

Goat

Tested: Human; Expected from sequence similarity: Human, Rat, Cat, Dog, Pig, Cow

497

DELSGERQRKRHKSD

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Peptide ELISA (EIA), Western Blot (WB)

Peptide ELISA: Antibody detection limit dilution 1: 64000. Western Blot: Approx 55kDa band observed in Human Liver lysates (calculated MW of 56. 0kDa according to NP_002383.2). In transfected HEK293 transiently expressing MDM2 bands of approx. 48kDa, 60KDa, 70kDa and 90kDa are observed. These bands are not observed in the non-transfected HEK293. The 80kDa band is endogenously epressed in the negative control. Recommended concentration: 0.3-1. 0ug/ml.

Immunogen: Peptide with sequence C-DELSGERQRKRHKSD, from the internal region of the protein sequence according to NP_002383.2. Epitope: Internal region

Note: This antibody is expected to recognize isoform MDM2 (NP_002383.2) only.

89993689

NP_002383.2

NM_002392.5

55,991 Da

AKT Phosphorylates Targets In The Cytosol Pathway (1269189); Adaptive Immune System Pathway (1269171); Androgen Receptor Signaling Pathway (198806); Apoptosis Pathway (198797); Aurora A Signaling Pathway (137925); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Cell Cycle Pathway (1269741); Cell Cycle Checkpoints Pathway (1269742); Cell Cycle Pathway (198811)

This gene encodes a nuclear-localized E3 ubiquitin ligase. The encoded protein can promote tumor formation by targeting tumor suppressor proteins, such as p53, for proteasomal degradation. This gene is itself transcriptionally-regulated by p53. Overexpression or amplification of this locus is detected in a variety of different cancers. There is a pseudogene for this gene on chromosome 2. Alternative splicing results in a multitude of transcript variants, many of which may be expressed only in tumor cells. [provided by RefSeq, Jun 2013]

MDM2: a ubiquitin ligase for p53, plays a central role in regulation of the stability of p53 via Akt-mediated MDM2 phosphorylation. Phosphorylation of MDM2 increases its interaction with p300, providing a platform to allow the assembly of the protein complex necessary for MDM2-mediated ubiquitination and degradation of p53. Phosphorylation of MDM2 also blocks its binding to p19ARF, increasing the degradation of p53. Facilitates the nuclear export of p53 and targets it for proteasome-mediated proteolysis. Eight alternatively spliced isoforms have been reported. Protein type: Ubiquitin ligase; Ubiquitin conjugating system; EC 6.3.2.19; Nucleolus; EC 6.3.2.-; Oncoprotein; Ligase; Inhibitor. Chromosomal Location of Human Ortholog: 12q14.3-q15. Cellular Component: cytoplasm; cytosol; nuclear body; nucleolus; nucleoplasm; nucleus; plasma membrane; protein complex; synapse. Molecular Function: enzyme binding; identical protein binding; ligase activity; p53 binding; peroxisome proliferator activated receptor binding; protein binding; SUMO ligase activity; ubiquitin protein ligase binding; ubiquitin-protein ligase activity; zinc ion binding. Biological Process: blood vessel development; blood vessel remodeling; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; establishment of protein localization; negative regulation of caspase activity; negative regulation of DNA damage response, signal transduction by p53 class mediator; negative regulation of transcription from RNA polymerase II promoter; negative regulation of transcription, DNA-dependent; peptidyl-lysine modification; positive regulation of cell proliferation; positive regulation of mitotic cell cycle; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; positive regulation of protein export from nucleus; protein complex assembly; protein destabilization; protein sumoylation; protein ubiquitination; protein ubiquitination during ubiquitin-dependent protein catabolic process; regulation of heart rate; regulation of protein catabolic process; response to antibiotic; response to carbohydrate stimulus; response to cocaine; response to drug; response to ether; response to iron ion; response to magnesium ion; response to morphine; traversing start control point of mitotic cell cycle; viral reproduction. Disease: Accelerated Tumor Formation, Susceptibility To

0.1 mg

300 USD